Crohn's Disease
FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s
A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.
AGA recommends use of fecal calprotectin, serum CRP to inform Crohn’s disease management
Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.
VIDEO: States with lower health, socioeconomic ranking have higher IBD-related mortality
VANCOUVER, British Columbia — Researchers found significant associations between state-level health disparities and poor inflammatory bowel disease-related outcomes, with low-ranking states demonstrating higher mortality rates.
GALAXI 1: Continued subcutaneous Tremfya benefits IV induction non-responders with Crohn’s
VANCOUVER, British Columbia — More than 50% of patients with Crohn’s disease who did not achieve clinical response at week 12 to IV Tremfya achieved response at week 48 after continuing subcutaneous therapy, according to a presenter.
FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases
The FDA has approved Wezlana as a Stelara biosimilar for the treatment of plaque psoriasis, psoriatic arthritis and other inflammatory diseases, according to an FDA press release.
Newly diagnosed psoriatic disease associated with autoimmune disease risk
Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.
Skyrizi achieves outcomes of clinical, endoscopic remission in patients with Crohn’s
Skyrizi demonstrated non-inferiority to Stelara in clinical remission at 24 weeks, as well as superiority in endoscopic remission at 48 weeks, in patients with moderate to severe Crohn’s disease, according to data presented at UEG Week.
VIDEO: Tremfya maintains clinical, endoscopic efficacy through 3 years in Crohn’s disease
In a Healio video exclusive, Jan Wehkamp, MD, PhD, reports that treatment with Tremfya maintained clinical remission and endoscopic response through 3 years among patients with moderate to severe Crohn’s disease.